A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31004502

Enrollment

Registered

2008-02-20

Start date

2008-05-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder symptoms Urological and Genital Diseases Overactive bladder symptoms

Interventions

Imipramine 25 mg once a day given orally vs placebo. Imipramine will be given for 6 weeks followed by placebo for 6 weeks and vice versa in the other arm of this cross-over trial.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years 2. Able to consent 3. Suffering from overactive bladder symptoms 4. Taking antimuscarinic treatment for detrusor overactivity

Exclusion criteria

Exclusion criteria: 1. Unable to consent 2. Pregnant 3. Breast feeding 4. Recent myocardial infarction 5. History of psychiatric illness 6. Taking monoamine oxidase inhibitors 7. <18 years

Design outcomes

Primary

Measure	Time frame
Urgency score questionnaire (Al Buheissi S, et al., 2008), carried out after 1 week of run-in period and at 2, 4, 6, 8, 10 and 12 weeks.	—

Secondary

Measure	Time frame
The following will be assessed after 1 week of run-in period and at 6 and 12 weeks: 1. 24 hour urinary frequency 2. Daily urinary Incontinence records 3. Patient preference for treatment 4. Incontinence Quality of Life questionnaire (I-QOL) score 5. Record of side effects	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026